Kasprzak v. Huang CA2/7

CourtCalifornia Court of Appeal
DecidedOctober 27, 2025
DocketB332483
StatusUnpublished

This text of Kasprzak v. Huang CA2/7 (Kasprzak v. Huang CA2/7) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kasprzak v. Huang CA2/7, (Cal. Ct. App. 2025).

Opinion

Filed 10/27/25 Kasprzak v. Huang CA2/7 NOT TO BE PUBLISHED IN THE OFFICIAL REPORTS California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

SECOND APPELLATE DISTRICT

DIVISION SEVEN

ROBERT KASPRZAK, B332483

Plaintiff and Respondent, (Los Angeles County Super. Ct. No. 23STCV09342) v.

CHARLES CHUNHUA HUANG et al.,

Defendants and Appellants. __________________________________

ROBERT KASPRZAK, B332499

Plaintiff and Respondent, (Los Angeles County Super. Ct. No. 23AHCP00291) v.

PASACA CAPITAL, INC.,

Defendant and Appellant. APPEALS from orders of the Superior Court of Los Angeles County, William A. Crowfoot, Judge. Affirmed. Ellis George, Eric M. George, Christopher T. Berg, and David J. Carroll for Defendants and Appellants. Wilmer Cutler Pickering Hale and Dorr, Thomas G. Sprankling, Christopher T. Casamassima, and Leah M. Fugere for Plaintiff and Respondent. ________________________

INTRODUCTION

These appeals arise from the trial court’s orders denying two motions to compel arbitration under an employment arbitration agreement between appellant Pasaca Capital, Inc. (Pasaca) and respondent Robert Kasprzak, the former chief legal officer of Pasaca. Kasprzak filed the two underlying actions giving rise to these appeals: a civil complaint against Pasaca and co-appellant Charles Huang, Pasaca’s founder and majority shareholder (the civil action); and a petition for writ of mandate seeking to review Pasaca’s books and records pursuant to Corporations Code section 1601 (the books and records action). The parties are also separately proceeding in an arbitration initiated by Pasaca alleging Kasprzak defrauded the company of over $100 million during his employment. Pasaca and Huang moved to compel arbitration of Kasprzak’s breach of fiduciary duty and unjust enrichment causes of action in the civil action, contending these claims were subject to an arbitration clause covering “any dispute or claim relating to or arising out of [the] employment relationship.” Pasaca also moved to compel arbitration of Kasprzak’s books and records action, arguing his shareholder status was intertwined

2 with his employment relationship. The trial court denied both motions. It concluded Kasprzak’s breach of fiduciary duty and unjust enrichment claims arose from a “co-venture” business relationship predating his formal employment and were therefore not “rooted in” the employment relationship for purposes of the arbitration clause, and his books and records action likewise was rooted in his pre-employment shareholder status. We affirm.

FACTUAL AND PROCEDURAL BACKGROUND

A. Kasprzak, Huang, and Others Form a Business Relationship and Launch a COVID-19 Test Supply Business In early 2020, Kasprzak, Huang, and three other individuals (Daniel Elliott, Kening Xu, and Shuning Luo) entered into an informal co-venture, initially envisioned as an international investments enterprise. When the COVID-19 pandemic began, the co-venture reinvented itself as a COVID-19 test supplier. The co-venture’s activities were ultimately folded into Pasaca, a shell company Huang created in 2016, with Pasaca’s share ownership divided among the co-venturers. Pasaca created a wholly owned subsidiary, Innova Medical Group, Inc. (Innova), to conduct the COVID-19 testing business. Innova agreed to pay two third-party sales intermediaries, Nano LiquiTec LLC and Disruptive Nanotechnology Ltd., a percentage of the sale price of the COVID-19 tests as commission. Innova secured contracts with the United Kingdom to provide COVID-19 testing kits, generating approximately $5 billion in sales in approximately a year and a half.

3 Kasprzak signed a subscription agreement, effective March 1, 2020, giving him the right to purchase 750,000 shares of Pasaca. Kasprzak purchased these 750,000 shares for $75,000, or 10 cents per share.

B. Kasprzak’s Employment Agreement and Termination On June 21, 2021, over a year after he purchased his shares, Kasprzak accepted the position of Pasaca’s chief legal officer, with his employment made retroactive to October 1, 2020. The two-page employment agreement included an arbitration provision stating, in relevant part: “in the event of any dispute or claim relating to or arising out of our employment relationship, you and the Company agree to an arbitration in which . . . all disputes between you and the Company shall be fully and finally resolved by binding arbitration.” The agreement made no reference to stock ownership, Kasprzak’s shares, or the subscription agreement. From 2020 to 2022, Pasaca compensated Kasprzak with a total of: (1) $1,481,012.99 in total pre-tax salary; (2) a $110,000 director’s fee; (3) a $15,000,000 director’s bonus; (4) dividends in the amount of $60,633,236; and (5) a watch worth $163,705. In early 2022, Kasprzak and Huang discussed Kasprzak’s resignation from Pasaca and agreed Pasaca would repurchase Kasprzak’s 750,000 shares for at least $75 million, and further agreed that Kasprzak would resign as an officer and director on a mutually agreed date. They eventually agreed the repurchase and resignation date would be September 30, 2022. On September 30, 2022, Pasaca instead terminated Kasprzak for alleged employment misconduct (as described

4 below), and contended in the subsequent books and records action that it “voided” his shares in the company at that time.

C. Arbitration Proceedings In February 2023, Pasaca initiated arbitration proceedings against both Kasprzak and Daniel Elliott, who had served as chief executive officer of Pasaca.1 Pasaca alleged Kasprzak and Elliott fraudulently negotiated reduced commission payments to the sales intermediaries, then siphoned the savings to themselves rather than passing them on to Innova or Pasaca. Pasaca also alleged Kasprzak and Elliott diverted over $106 million through this scheme, by creating a company (Nano Holdings LLC) with a similar name to the two legitimate third-party sales intermediaries (Nano LiquiTec LLC and Disruptive Nanotechnology Ltd.). Kasprzak, in his capacity as Pasaca’s chief legal officer, also had negotiated Elliott’s separation terms in 2022, which included Pasaca paying Elliott over $105 million and a release of all claims against Elliott. Pasaca sought to recover the alleged $106 million in fraudulent commission payments, the $77 million in salary and benefits Kasprzak received, and the $105 million payout to Elliott that Kasprzak negotiated. In April 2023, Kasprzak responded to Pasaca’s claims in arbitration and asserted two indemnification counterclaims. On the first page of his response, Kasprzak stated he was pursuing litigation against Pasaca and Huang, and that he “provides this Response out of an abundance of caution, does not concede jurisdiction by JAMS, the arbitrability of the claims asserted by

1 Innova is also a claimant in the arbitration. For ease of reference, and as relevant here, we refer solely to Pasaca.

5 Claimants or the propriety of this proceeding, and does not waive any defenses to which he may be entitled.” Kasprzak’s first affirmative defense asserted that Pasaca’s claims were “barred to the extent any or all of [its] claims are not subject to arbitration” and “further barred to the extent the employment letter compels arbitration only of claims not asserted” by Pasaca.

D.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Pinnacle Museum Tower Ass'n v. Pinnacle Market Development (US), LLC
282 P.3d 1217 (California Supreme Court, 2012)
Reserve Insurance Co. v. Pisciotta
640 P.2d 764 (California Supreme Court, 1982)
Victoria v. Superior Court
710 P.2d 833 (California Supreme Court, 1985)
O'MALLEY v. Petroleum Maintenance Co.
308 P.2d 9 (California Supreme Court, 1957)
Schnabel v. Superior Court
854 P.2d 1117 (California Supreme Court, 1993)
National Assn. of Wine Bottlers v. Paul
268 Cal. App. 2d 741 (California Court of Appeal, 1969)
Doe v. California Dept. of Justice
173 Cal. App. 4th 1095 (California Court of Appeal, 2009)
Janis v. California State Lottery Commission
80 Cal. Rptr. 2d 549 (California Court of Appeal, 1998)
Khalatian v. Prime Time Shuttle CA2/8
237 Cal. App. 4th 651 (California Court of Appeal, 2015)
Panoche Energy Center, LLC v. Pacific Gas & Electric Co.
1 Cal. App. 5th 68 (California Court of Appeal, 2016)
La Mirada Avenue Neighborhood Ass'n of Hollywood v. City of Los Angeles
2 Cal. App. 5th 586 (California Court of Appeal, 2016)
Desert Outdoor Advertising v. Superior Court
196 Cal. App. 4th 866 (California Court of Appeal, 2011)
Esparza v. KS Indus., L.P.
221 Cal. Rptr. 3d 594 (California Court of Appeals, 5th District, 2017)
Douglass v. Serenivision, Inc.
229 Cal. Rptr. 3d 54 (California Court of Appeals, 5th District, 2018)
Howard v. Goldbloom
241 Cal. Rptr. 3d 743 (California Court of Appeals, 5th District, 2018)
Salgado v. Carrows Rests., Inc.
244 Cal. Rptr. 3d 849 (California Court of Appeals, 5th District, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Kasprzak v. Huang CA2/7, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kasprzak-v-huang-ca27-calctapp-2025.